Chargement en cours...
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
Nintedanib is a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis (IPF). We investigated the cardiovascular safety of nintedanib using pooled data from the TOMORROW and INPULSIS trials. Cardiovascular events were assessed post hoc in patients with a history of atherosclerotic car...
Enregistré dans:
| Publié dans: | Eur Respir J |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
European Respiratory Society
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6766682/ https://ncbi.nlm.nih.gov/pubmed/31285303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/13993003.01797-2018 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|